Cladribine as effective as fingolimod in highly active relapsing multiple sclerosis
Cladribine tablets and fingolimod have similar marketing authorisations in Europe for the treatment of patients with highly active relapsing multiple sclerosis (HA-RMS). In the absence of direct head-to-head studies, real-world data are important to assess the comparative effectiveness of these oral disease-modifying therapies (DMTs).An original article entitled “Comparative effectiveness...
Cladribine tablets and fingolimod have similar marketing authorisations in Europe for the treatment of patients with highly active relapsing multiple sclerosis (HA-RMS). In the absence of direct head-to-head studies, real-world data are important to assess the comparative effectiveness of these oral disease-modifying therapies (DMTs).
An original article entitled “Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study” by Brownlee et al. compared cladribine therapy with fingolimod therapy in terms of relapse rates among patients with highly active relapsing MS and concluded noninferiority of cladribine treatment compared with fingolimod therapy in terms of relapse rates over a short follow-up period. They related Cladribine tablets to fewer discontinuations and treatment switches.
They added the need for longer follow-ups to determine the maintenance of this effectiveness and the availability of more data about safety and tolerability.
Considering the background, they said, Cladribine tablets and fingolimod have similar marketing authorisations in Europe for managing highly active relapsing multiple sclerosis (HA-RMS) patients.
There is a need for real-world data to assess the comparative effectiveness of these oral disease-modifying therapies (DMTs).
The present study compared relapse rates between patients receiving either cladribine tablets or fingolimod.
The study was conducted in the UK and Germany and assessed non-inferiority in relapse rates of cladribine tablets versus fingolimod in HA-RMS patients.
The results of the study are:
- The cohort had 1,095 HA-RMS patients.
- A total of 610 patients, constituting 55.7%, received cladribine tablets, while 485 patients constituting 44.3%, received fingolimod.
- Some patients discontinued cladribine tablets / switched to another DMT compared to fingolimod (0.2% versus 3.5%, respectively).
- The adjusted annualised relapse rate (ARR) for cladribine tablets and fingolimod was 0.10 and 0.14, respectively.
- The adjusted ARR ratio was 0.68.
In this study, they noted that cladribine tablets were non-inferior to fingolimod one year after treatment initiation.
Further reading:
https://www.msard-journal.com/article/S2211-0348(23)00293-6/fulltext
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd